In a report released on January 9, Aaron Grey from Alliance Global Partners reiterated a Buy rating on Tilray (TLRY – Research Report), with a price target of $2.25. The company’s shares closed yesterday at $2.00.
According to TipRanks, Grey is an analyst with an average return of -20.5% and a 30.21% success rate. Grey covers the Healthcare sector, focusing on stocks such as Canopy Growth, OrganiGram Holdings, and Tilray.
In addition to Alliance Global Partners, Tilray also received a Buy from TD Cowen’s Vivien Azer in a report issued on January 9. However, yesterday, Piper Sandler assigned a Hold rating to Tilray (NASDAQ: TLRY).
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $3.59 and a one-year low of $1.50. Currently, Tilray has an average volume of 17.35M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tilray (TLRY) Company Description:
Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It also supplies cannabis products to patients in a number of countries spanning five continents through its subsidiaries in Australia, Canada and Germany and it produces medical cannabis in Canada and Europe. The company was founded on January 24, 2018 and is headquartered in Nanaimo, Canada.
Read More on TLRY:
